Just sold my shares in Merant. (I know there is probably a few pence more in it. BUT, BUT BUT!!!!


Bought with it some more Bespac. I think it should go on the following information#, but spread is large.

2004 2005
Broker Date Rec Pre-tax ( ) EPS ( p ) DPS ( p ) Pre-tax ( ) EPS( p ) DPS( p )
Investec Securities 27 - 01 - 04 BUY 10.22 26.70 19.10 10.95 28.61 19.10
Seymour Pierce Ltd 01 - 03 - 04 OVAL 7.10 18.60 19.10 10.20 26.60 19.10
Numis Securities Ltd 26 - 02 - 04 BUY 12.00 32.80 15.00 40.00
Nomura Research Institute 02 - 02 - 04 BUY 13.00 35.50 19.10 23.00 62.80 19.10
Dryden Wealth Management Ltd 20 - 01 - 04 HOLD

Strong Buy Buy Weak Buy Weak Buy/Hold Hold Weak Sell/Hold Weak Sell Sell Strong Sell
0 3 0 0 1 0 0 0 1





RPT Bespak drug-delivery deal nears European approval, shares rise (Repeating to clarify nature of deal, adds share price other background) LONDON (AFX) - Bespak PLC said the European Medicines Evaluation Agency had accepted a filing by Pfizer Inc and Aventis SA who are both seeking rights to market Exubera, a diabetes treatment which is inhaled in powdered form. Bespak said it will manufacture the drug delivery device under an arrangement with Nektar Therapeutics, Inc, a US company which developed both Exubera and the means of delivering it. In a statement, Bespak said the timing of full scale production is as yet unknown and will depend in part on the speed of the regulatory review process. Pfizer and Aventis are seeking approval to market Exubera to adult patients with Type 1 and Type 2 diabetes. At 8.20 am Bespak was among the best performing small-cap stocks in the London market, gaining 22-1/2 pence, or 4.2 pct, to 557-1/2.

Why are all the buys marked down as unknown ? i bought some today and monday and they also were shown as unknown.

This information may be of help to you. There are a few problems with inhalants and effectiveness. This may be part of the reservations but the information below may be helpful. I am holding 2370 Shares in this company

If you have trouble in reading this info I ca send it you as an word attachment
in an E-mail

Ratio estimates 2003 2004 2005(e)
Earnings per share (EPS) (in BPC) 32.26 34.72 35.64
Price earnings ratio 15.03 13.97 13.61



Cash flow per share (in BPC) 38.10 55.20 n/a
Net assets per share (in BPC) 254.82 263.60 280.23




Plan numbers 2003 2004 2005(e)
Sales (in Mio. GBP) 83.18 78.37 84.00
EBIT (in Mio. GBP) 11.12 10.71 12.95



EBITDA (in Mio. GBP) 18.80 18.85 21.18
Net debt (in Mio. GBP)** -12.32 -14.45 -21.65




Recent AFX news relating to BESPAK ORD 10P
STOCKWATCH Bespak up on robust FY results, optimistic outlook
LONDON (AFX) - Shares in Bespak PLC advanced in tandem with the wider market in early deals, after the medical devices group reported a robust set of results for the full year which saw underlying pretax profits almost tripling. Investec analyst Sebastien Jantet said the results exceed his expectations, driven by better-than-expected revenue, cost savings and a lower tax rate than he had anticipated. "Bespak's better-than-expected cash position and ungeared balance sheet means that it is ...Wednesday, 07/07/04, 09:25

Bespak FY pretax pre-ex 11.55 mln stg vs 4.2 mln
LONDON (AFX) - Bespak PLC 52 weeks to May 1 2004 Sales - 83.18 mln stg vs 88.31 mln Pretax profit before exceptionals - 11.55 mln stg vs 4.2 mln Pretax profit - 9.09 mln stg vs 3.28 mln EPS before exceptionals - 31.7 pence vs 11.5 EPS - 24.8 pence vs 10.5 Final div - 12.1 pence, unchanged Total div - 19.1 pence, unchanged vjt/ Wednesday, 07/07/04, 08:04

Bespak upbeat as FY underlying pretax almost triples to 11.6 mln stg - UPDATE
(Adds further detail from results statement) LONDON (AFX) - Medical devices company Bespak PLC said underlying pretax profits almost tripled in the year to May 1 as cost cuts and efficiency gains more than offset a 6 pct fall in turnover. The group said its financial performance in the year was ahead of board expectations and looking ahead, it added its expectations are unchanged for the current year. Pretax profit before exceptionals rose 174 pct to 11.6 mln stg from 4.2 mln a year ...Wednesday, 07/07/04, 07:53

Bespak upbeat as FY underlying pretax almost triples to 11.6 mln stg
LONDON (AFX) - Medical devices company Bespak PLC said underlying pretax profits almost tripled in the year to May 1 as cost cuts and efficiency gains more than offset a 6 pct fall in turnover. The group said its financial performance in the year was ahead of board expectations and looking ahead, it added its expectations are unchanged for the current year. Pretax profit before exceptionals rose 174 pct to 11.6 mln stg from 4.2 mln a year earlier as overall turnover slipped 6 pct to 83. ...Wednesday, 07/07/04, 07:35

Bespak signs development agreement with ML Labs respiratory unit
LONDON (AFX) - Bespak PLC said it signed a key new development agreement with ML Laboratories PLC's Innovata Biomed Ltd (IB), a provider of inhalation technology. Under the pact, Bespak will develop IB's new C200 multi-dose dry powder inhaler device for the delivery of combination drug therapies for diseases such as asthma. newsdesk@afxnews.com

Thanks for the info , i have emailed them regarding the inhalants . i have been watching the share trades over the past weeks, do you thing the mm are trying to buy stock for a big order?

Aldwickk

Thanks for E-mail. I think the information about getting the drug to the part of the lung for it to be effective has always been a problem. Nevertheless inhalers and steroids via have been very effective and revolutionised the treatment of Asthma.

But the information which switched me on to the "BPK" was the possibility of using the inhaler method for conveyance of "drugs" in the treatment of diabetics. Instead of injections. I also wondered whether there was a potential for Anti-biotic treatment in treatment of Chest Infections.

Again I will have to wait and see.


At the moment I think my portfolio is a balanced a little to much with Wait and See shares. I think I need to invest in a few with proven profits and highish yields.

Aldwickk
Thanks for E-mail. Interesting

17,405 trade near the close at 467.50p offer price marked up to 485p+10p so must be a buy.

Fred1new.

That 128,041 sell yestaday as been showing as a buy this morning.

I think BPK is on the move up. Trend line crossed. MA 5 10 50 crossed. Volume on break good, but smaller to-day.

Have a look for yourselves. Should please Aldwicck and Douggie

Fred.

What do you make of the last two 10,000 T trades, one marked as buy other a sell but both same price , i thing they might be both buys, it left the buy price at 493p, might see it adjusted to 480p monday.

I am not sure of the significance of the 2 protected trades. But think that if it goes above 273 on Monday this will reinforce the reversal and it should climb slowly until next Financial Update 20/1/2005. BE patient it will get there.

Fred.

Thing those T trades Where a rollover. A few weeks ago i doubled my holding by taking a spreadbet out when the price was at 440p, just before Aviva took a 7% stake. P.S. 100% sure it will be above 273p monday. lol.

Currency GBp 20 Mins Delayed Fridays closing price.
Mid 480.50 Today's Open 472.50
Change +8.00 Today's High 472.50
% Change +1.66 Today's Low 472.50
Bid 468.00 Previous Close 472.50
Ask 493.00 Year High Price: 627.50
Volume 29695 Year Low Price: 433.00

Aldwickk.

Thank you.

Let us assume I was drunk at the time of my lasting posting on this thread. I should have typed 473. My beliefs are transferable. Like you I think it should do well.
I have a feeling I was mulling over stop losses for TEP, when I wrote 273. (Not red wine.)

Aldwickk.


YOU probably already have read the below.


SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) Name of company: Bespak plc

2) Name of shareholder having a major interest: UBS AG (acting through UBS
Global Asset Management Life Ltd)

3) Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18: Not stated

4) Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them: Not stated

5) Number of shares/amount of stock acquired: Not stated

6) Percentage of issued class: N/A

7) Number of shares/amount of stock disposed: Not stated

8) Percentage of issued class: N/A

9) Class of security: Ordinary

10) Date of transaction: Not stated

11) Date company informed: 3 November 2004

12) Total holding following this notification: 812,276

13) Total percentage holding of issued class following this notification: 3.03

14) Any additional information: Shares in issue 26,805,889

15) Name of contact and telephone number for queries:Louise Scott, 01908 525240

16) Name and signature of authorised company official responsible for making
this notification: Louise Scott, Company Secretary


Date of notification: 3 November 2004

For more information on the Bespak Group please visit our Website at http://
www.bespak.com/






Director Shareholding - Bespak PLC

RNS Number:2907FBespak PLC16 November 2004 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS1)Name of company: Bespak plc2) Name of director: Martin P Hopcroft3) Please state whether notification indicates that it is in respect of holdingof the shareholder named in 2 above or in respect of a non-beneficial interestor in the case of an individual holder if it is a holding of that person'sspouse or children under the age of 18 or in respect of a non-beneficialinterest:Shareholder named above - beneficial holding4) Name of the registered holder(s) and, if more than one holder, the number ofshares held by each of them (if notified):5) Please state whether notification relates to a person(s) connected with theDirector named in 2 above and identify the connected person(s):6) Please state the nature of the transaction. For PEP transactions pleaseindicate whether general/single co PEP and if discretionary/non discretionary:7) Number of shares/amount of stock acquired: 2,0008) Percentage of issued class: 0.007469) Number of shares/amount of stock disposed:10) Percentage of issued class:11) Class of security: Ordinary shares of 10p per share12) Price per share: 4.7613) Date of transaction: 16 November 200414) Date company informed: 16 November 200415) Total holding following this notification: 3,64116) Total percentage holding of issued class following this notification: 0.0136If a director has been granted options by the company please complete thefollowing boxes17) Date of grant:18) Period during which or date on which exercisable:19) Total amount paid (if any) for grant of the option:20) Description of shares or debentures involved: class, number:21) Exercise price (if fixed at time of grant) or indication that price is to befixed at time of exercise:22) Total number of shares or debentures over which options held following thisnotification:23) Any additional information: Number of shares in issue 26,805,88924) Name of contact and telephone number for queries: Louise Scott, CompanySecretary 01908 52524025) Name and signature of authorised company official responsible for makingthis notification: Louise Scott, Company SecretaryDate of Notification: 16 November



Sorry it is difficult for me to read. Suck it into Word it should be easier. Anyway it shows there is a little confidence in the future. BE Patient. I wish I was sometimes.

Fred.
How do you thing the falling Dollar will effect they sales.

Up 16p today, anybody know why , apart from a few buys.

aldwickk Sorry for not responding. Don't really know. Depends whether the deal or arrangements with Nektar are in form of licence or not. Not sure what proportion of sales ill be in the US.

Up 5p this morning on no volume and no news.

back to top

Bespak PLC
16 December 2004


SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) Name of company: Bespak plc

2) Name of shareholder having a major interest: Aviva plc and its subsidiary,
Morley Fund Management Limited

3) Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18: Not stated

4) Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them:

BNY Norwich Union Nominees Limited - 347,402 (material)

Chase GA Group Nominees Limited - 1,118,606 (material)

CUIM Nominee Limited - 439,822 (material)

5) Number of shares/amount of stock acquired: 37,999

6) Percentage of issued class: 0.142

7) Number of shares/amount of stock disposed:

8) Percentage of issued class:

9) Class of security: Ordinary

10) Date of transaction: 14 December 2004

11) Date company informed: 16 December 2004

12) Total holding following this notification: 1,905,830

13) Total percentage holding of issued class following this notification: 7.11

14) Any additional information: Total shares in issue - 26,805,889

15) Name of contact and telephone number for queries: Louise Scott 01908 525240

16) Name and signature of authorised company official responsible for making
this notification: Louise Scott, Company Secretary

Date of notification : 16 December 2004

LONDON (AFX) - Bespak PLC said it is looking for acquisitions to reduce the company's reliance on components sold to pharmaceutical companies, as the medical device maker reported a drop in first-half profit.

Pretax profit fell to 1.8 mln stg from 2.9 mln last year, dented by a 3.9 mln charge on the closure of a US manufacturing facility. After costs, pretax rose rose 16 pct to 5.7 mln stg.

Sales fell 4 pct to 38.9 mln stg in the 26 weeks to Oct 30, and the company said it will maintain its interim dividend at 7 pence.

The company said the closure of the US plant should improve on-going operating profit by approximately 700,00 stg a year, after further estimated exceptional cash costs of 2 mln stg.

'The Group has performed very well in the first half. Closing the Cary facility removes an under-performing part of the business, and news about the Exubera(R) filing is encouraging,' Mark Throdahl, chief executive said.

Bespak said Pfizer recently announced it is in the final stages of preparing an NDA for Exubera(R), for which its manufactures the inhalation device.

'We are now turning our attention to acquiring specialty medical businesses that play to our strengths and enable us to generate more consistent sales growth.'

The company said it is looking to boost organic growth with selective acquisitions that either infill current businesses or take the group into new, but related, product areas. Acquisitions will initially be financed from cash resources, it added.

It hopes that the addition of businesses which manufacture specialty devices and other products specified by clinicians will reduce its reliance on components sold to pharmaceutical companies, which often entail long development programmes.

newsdesk@afxnews.com

ab

When they all said this was down and out I said buy at 523P on USA potential.

GO YOU LITTLE DARLIN'